Can you provide the average price target for EXELIXIS INC stock?
27 analysts have analysed EXEL and the average price target is 48.11 USD. This implies a price increase of 16.57% is expected in the next year compared to the current price of 41.27.
NASDAQ:EXEL • US30161Q1040
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EXELIXIS INC (EXEL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-11 | Stifel | Maintains | Hold -> Hold |
| 2026-02-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-02 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-08 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2026-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-06 | UBS | Maintains | Neutral -> Neutral |
| 2025-11-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-10-21 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-10-21 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-10-21 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-17 | Barclays | Initiate | Equal-Weight |
| 2025-09-17 | Goldman Sachs | Initiate | Buy |
| 2025-09-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.83B 13.60% | 2.169B 18.49% | 2.32B 6.98% | 2.637B 13.66% | 2.99B 13.39% | 3.324B 11.17% | 3.551B 6.83% | 3.231B -9.01% | 2.988B -7.52% | 3.019B 1.04% | 3.184B 5.47% | |
| EBITDA YoY % growth | 196.602M -11.60% | 718.752M 265.59% | 921.756M 28.24% | 1.108B 20.21% | 1.272B 14.80% | 1.562B 22.80% | 652.8M -58.21% | 672.18M 2.97% | 679.32M 1.06% | N/A | N/A | |
| EBIT YoY % growth | 170.885M -15.19% | 689.949M 303.75% | 892.701M 29.39% | 1.019B 14.15% | 1.209B 18.65% | 1.451B 20.02% | 1.787B 23.16% | 1.674B -6.32% | 1.33B -20.55% | 1.38B 3.76% | 1.687B 22.25% | |
| Operating Margin | 9.34% | 31.81% | 38.48% | 38.64% | 40.43% | 43.65% | 50.32% | 51.81% | 44.51% | 45.71% | 52.98% | |
| EPS YoY % growth | 0.64 12.28% | 1.85 189.06% | 2.77 49.73% | 3.14 13.25% | 3.82 21.69% | 4.88 27.88% | 5.40 10.57% | 4.47 -17.20% | 1.78 -60.22% | 1.97 10.71% | 2.35 19.17% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.73 32.70% | 0.76 16.91% | 0.86 25.12% | 0.88 -0.04% | 0.82 11.81% | 0.85 11.41% | 0.90 3.97% | 0.94 6.68% | 1.06 30.00% | 1.09 28.92% | 1.13 26.14% |
| Revenue Q2Q % growth | 619.87M 11.60% | 643.18M 13.18% | 674.56M 12.85% | 709.51M 18.52% | 740.93M 19.53% | 773.88M 20.32% | 820.4M 21.62% | 855.33M 20.55% | 881.22M 18.93% | 906.88M 17.19% | 939.36M 14.50% |
| EBITDA Q2Q % growth | 237.7M 22.40% | 262.02M 14.79% | 287.51M 3.25% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 232.23M 24.28% | 246.9M 15.60% | 250.7M -2.21% | 242.62M 2.84% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
27 analysts have analysed EXEL and the average price target is 48.11 USD. This implies a price increase of 16.57% is expected in the next year compared to the current price of 41.27.
EXELIXIS INC (EXEL) will report earnings on 2026-05-11, after the market close.
The consensus EPS estimate for the next earnings of EXELIXIS INC (EXEL) is 0.73 USD and the consensus revenue estimate is 619.87M USD.
The expected long term growth rate for EXELIXIS INC (EXEL) is 11.89%.